Keyword: Geoffrey Porges

Celgene’s stock has taken a beating thanks to a string of bad news. But the situation isn’t as dire as its share price suggests, one analyst insists.

Pfizer just got some backup on its quest to snag a nod for ulcerative colitis med Xeljanz. On Thursday, an FDA AdComm voted to approve the drug.

AbbVie may not seem like the kind of company to chase down mammoth deals. But that doesn’t mean it won’t do just that.

Industry watchers have tabbed Alexion as a potential activist target. And one prominent activist reportedly wants to take advantage of the opportunity.

Which biotech company does Vertex admire? Hint: It’s one some analysts think the CF drugmaker should bought a long time ago.

AbbVie and Roche amped up blockbuster hopes for Venclexta, their blood cancer drug, with data pointing the way to a big new approval.

Biogen and AbbVie’s MS drug Zinbryta faces new restrictions in Europe at a time when tough payers and new challengers are roiling the field.

Last summer’s most ballyhooed M&A deal—Pfizer’s $14 billion buyout of Medivation—doesn’t look so impressive anymore, thanks to data rolled out at ASCO.